Furthermore, ESCC patients with high ITGB2 expression exhibit shorter overall survival (OS), disease‐specific survival (DSS), and progression‐free interval (PFI) compared to those with low ITGB2 expression. This evidence concerns the gene ITGB2 and esophageal squamous cell carcinoma.